Key Points
- John C.M. Farquhar, Heartflow's CEO, sold 12,837 shares on March 10 at an average price of $22.66 for about $290,886, leaving him with 581,450 shares (a 2.16% reduction in ownership).
- Heartflow stock was trading at $20.68, below its 50‑day ($27.83) and 200‑day ($30.76) moving averages and near its 12‑month low of $20.13, with a market cap of roughly $1.76 billion and a negative P/E of -11.41.
- Analysts have a consensus rating of "Moderate Buy" with a $38.50 target price (five Buy, two Hold, one Sell), and several firms recently raised targets into the $38–$40 range.
Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) CEO John C.M. Farquhar sold 12,837 shares of the stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $22.66, for a total value of $290,886.42. Following the completion of the transaction, the chief executive officer owned 581,450 shares in the company, valued at $13,175,657. The trade was a 2.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
John C.M. Farquhar also recently made the following trade(s):
- On Tuesday, February 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $27.46, for a total value of $619,552.52.
Heartflow Trading Down 0.6%
Heartflow stock traded down $0.12 during mid-day trading on Friday, hitting $20.68. The stock had a trading volume of 441,490 shares, compared to its average volume of 1,396,040. The stock has a 50-day simple moving average of $27.83 and a two-hundred day simple moving average of $30.76. The stock has a market capitalization of $1.76 billion and a PE ratio of -11.41. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $41.22.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of HTFL. Caitong International Asset Management Co. Ltd bought a new stake in shares of Heartflow during the fourth quarter worth $27,000. TFC Financial Management Inc. bought a new position in Heartflow during the 3rd quarter worth about $40,000. Russell Investments Group Ltd. acquired a new stake in shares of Heartflow in the 4th quarter valued at about $45,000. Legal & General Group Plc acquired a new position in shares of Heartflow during the third quarter worth about $59,000. Finally, Strs Ohio bought a new position in shares of Heartflow during the fourth quarter worth about $99,000.
Analyst Ratings Changes
A number of research firms have commented on HTFL. JPMorgan Chase & Co. lifted their target price on shares of Heartflow from $36.00 to $40.00 and gave the stock an "overweight" rating in a report on Thursday, November 13th. Weiss Ratings reissued a "sell (d)" rating on shares of Heartflow in a research note on Monday, December 29th. Stifel Nicolaus boosted their target price on Heartflow from $35.00 to $40.00 and gave the stock a "buy" rating in a research report on Thursday, November 13th. Wells Fargo & Company initiated coverage on shares of Heartflow in a research note on Wednesday, January 28th. They set an "overweight" rating and a $38.00 price objective on the stock. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $40.00 target price on shares of Heartflow in a research note on Monday. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Heartflow has an average rating of "Moderate Buy" and a consensus target price of $38.50.
Read Our Latest Analysis on Heartflow
About Heartflow
(
Get Free Report)
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
